Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
Frontiers in Pharmacology · 13.11.2024 · 15
DOI: 10.3389/fphar.2024.1461398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.11.2024. Verfasst von Hui Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanxi Cardiovascular Disease Hospital, Taiyuan, Shanxi, China. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown notable advancements in managing blood sugar control. Nevertheless, there remains a gap in real-world data regarding the variation in acute pancreatitis (AP) risk among different GLP-1 RAs. Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Methods
We described a case series of patients experiencing AP while on GLP-1 RAs. Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) regarding suspected adverse events of AP linked to GLP-1 RAs from January 2005 to September 2023.
Results
Our case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs. Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs. The median age of the patients included in our study was 57 years (range: 14–99), with 98.3% of cases classified as serious. Signals indicating AP were observed across all GLP-1 RAs, with particular emphasis on exenatide and liraglutide.
Conclusion
There is a notable reporting signal of AP associated with all GLP-1 RAs. Healthcare providers must remain vigilant and closely monitor this potentially life-threatening adverse event.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Shanxi Cardiovascular Disease Hospital, Taiyuan, Shanxi, China.
- Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
- Department of Pharmacy, Shanxi Traditional Chinese Medical Hospital, Taiyuan, Shanxi, China.
Zitieren
APA
Guo, H., Guo, Q., Li, Z., & Wang, Z. (2024). Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1461398
Vancouver
Guo H, Guo Q, Li Z, Wang Z. Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1461398
BibTeX
@article{Guo2024,
author = {Guo, Hui and Guo, Qian and Li, Zhiqiang and Wang, Ze},
title = {Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1461398}
}
EUVIMED